SAFE-HEARTNCT07916337
3D Versus 2D Strain Echocardiography for Early Detection of Cardiotoxicity During Cancer Therapy
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Change in 3D left ventricular strain parameters compared with 2D global longitudinal strain during follow-up
Timeframe: From baseline (before start of cancer therapy) through 12 months of follow-up (breast cancer) and 24 months of follow-up (lymphoma and sarcoma)
Secondary (10)
Change in 3D left ventricular ejection fraction compared with 2D left ventricular ejection fraction
Change in right ventricular free wall longitudinal strain
Incidence of cancer therapy-related cardiac dysfunction (CTRCD)
Area under the receiver operating characteristic curve of early change in 3D strain parameters for prediction of CTRCD
Correlation between change in 3D and 2D strain parameters and change in high-sensitivity troponin I
Show 5 moreShow less
Proportion of echocardiographic examinations with image quality adequate for 3D strain analysis
Correlation between 3D strain parameters and cardiac magnetic resonance measures
Number of participants with initiation of heart failure medication, hospitalisation for heart failure or all-cause death
Correlation between change in 3D and 2D strain parameters and change in NT-proBNP
Change in 3D right ventricular ejection fraction
Arms and interventions
Breast cancer
Adults with breast cancer scheduled for anthracycline and/or HER2-targeted therapy. 2D and 3D echocardiography and cardiac biomarkers (troponin I, NT-proBNP) at baseline and thereafter according to clinical indication, typically every 3-4 months. Biobank samples at baseline and approximately 6 months.
Lymphoma and sarcoma
Adults with lymphoma or sarcoma scheduled for anthracycline-based therapy. 2D and 3D echocardiography and cardiac biomarkers (troponin I, NT-proBNP) at baseline, 6 months and 24 months after treatment start. Biobank samples at baseline and approximately 6 months.
Sites
1 site in 1 country
- Skåne University Hospital Lund and MalmöLund, Skåne County, Sweden